New study for Architect Tacrolimus assay (Abbott Diagnostics)

A new study published in the journal Clinical Chemistry reported Architect Tacrolimus assay from Abbott Diagnostics provides accurate and consistent medication monitoring for patients taking tacrolimus, an immunosuppressive medication, after receiving solid organ transplantation. This study showed tacrolimus values were not comparable between laboratories and across methods, but the Architect assay was close to the target values and comparable from lab to lab."A transplant patient might receive an organ at one facility and be monitored somewhere else. If that location uses an assay with poorer accuracy and precision, it could result in incorrect dosage decisions, so it is critical that test results measuring tacrolimus medication levels be comparable from site-to-site," said Dr. David Holt, co-author of the paper and Emeritus Professor of Bioanalytics at the University of London ,